Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 6/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554037 | 0.95 | MAPT (0.40) | GAAKMT2A | |
| SCHEMBL1506077 | 0.91 | NPC1 (0.37) | CDK5CDK5R1NAMPTKMT2A | |
| SCHEMBL2132617 | 0.90 | CYP19A1 (0.41) | CDK5CDK5R1 | |
| SCHEMBL1505611 | 0.89 | NAMPT (0.41) | CDK5CDK5R1NAMPTGAAKMT2A | |
| SCHEMBL2131025 | 0.89 | NPC1 (0.37) | CDK5CDK5R1NAMPTKMT2A | |
| SCHEMBL2133723 | 0.89 | MAPK1 (0.38) | ROCK1 | |
| SCHEMBL2135642 | 0.88 | TGFBR1 (0.37) | CDK5CDK5R1 | |
| SCHEMBL2132961 | 0.88 | CDK5 (0.36) | CDK5CDK5R1KMT2AROCK2ROCK1 | |
| SCHEMBL1505684 | 0.87 | PKM (0.38) | CDK5CDK5R1NAMPT | |
| SCHEMBL1553153 | 0.87 | KDM4E (0.36) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | CDK5 2131/4885CDK5R1 2969/4885NAMPT 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.